About Rheincell Therapeutics
Rheincell Therapeutics is a company based in Langenfeld (Germany) founded in 2017 was acquired by Catalent in June 2021. Rheincell Therapeutics operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Langenfeld, Germany
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Rheincell Therapeutics Gmbh
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Rheincell Therapeutics
Detailed funding history for Rheincell Therapeutics
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Rheincell Therapeutics
Rheincell Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Catalent.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
CDMO offering drug and biologics development services
|
Locked | Locked | Locked |
Investor details for Rheincell Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Rheincell Therapeutics
Investment portfolio details for Rheincell Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Rheincell Therapeutics
Detailed financials for Rheincell Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Rheincell Therapeutics Comparisons
Peer comparison for Rheincell Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Rheincell Therapeutics
Rheincell Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of Rheincell Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Rheincell Therapeutics
Complete news archive for Rheincell Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rheincell Therapeutics
Rheincell Therapeutics was founded in 2017.
Rheincell Therapeutics is headquartered in Langenfeld, Germany. It is registered at Langenfeld, North Rhine-westphalia, Germany.
Jurgen Weisser is the current CEO of Rheincell Therapeutics.
Rheincell Therapeutics was founded in 2017 in Langenfeld, Germany, within the biotechnology sector. Focus is placed on induced pluripotent stem (iPS) cells as a platform for cell-based therapies. A master cell bank is maintained to serve as starting material for various therapeutic applications, aiming to reduce immune rejection in recipients. Operations center on creating scalable sources for iPSC-derived treatments.
Rheincell Therapeutics's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Rheincell Therapeutics has 1 investor. Key investors include Catalent.